maliqun61 schreef op 7 augustus 2018 08:24:
Ook maar hier neergezet.
Bron: analistenrapport Roth Capital (Scott R. Henry) dd 26 juli 2018
Eerste blik opvallend: koersdoelverhoging Euro 2 --> Euro 2,50
Omzetverlaging: jaaromzet Euro 135,1 miljoen ---> Euro 129,6 miljoen
Reiterate Buy rating, PT to €2.50. Pharming is benefiting from growing Ruconest into a significant product that is driving profitability. However, the company is now turning Ruconest into a platform pipeline drug that could have magnitudes of greater revenue potential. We increased our price target to €2.50 to reflect this greater upside.
Pharming reported 2Q18 results that were within our expectations. The key takeaways, in our opinion, include 1) Ruconest stabilization is occurring with competitive supply back on stream (as expected), 2) we tweaked our #'s downward to reflect a slightly lower 1H18 Ruconest base and higher R&D spending, and 3) the company's pipeline has expanded considerably with multiple catalysts for 2H18. Reiterate Buy rating with price target increased to €2.50/share to reflect increased pipeline visibility.